This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

GE to buy cell-culture, gene-modulation units from Thermo Fisher Scientific

( January 6, 2014, 15:11 GMT | Official Statement) -- MLex Summary: GE Healthcare, the medical technologies and services division of NYSE-listed General Electric, has agreed to acquire NYSE-listed serving science company Thermo Fisher Scientific's cell culture media and sera, and gene modulation and magnetic beads businesses for approximately $1.06 billion.  The deal, which is subject to regulatory approvals, is expected to close in the first part of 2014.Statement follows in full....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login